The Library
Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans : evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment
Tools
Tan, Bee K., Hallschmid, Manfred, Kern, Werner, Lehnert, Hendrik and Randeva, Harpal S. (2011) Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans : evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. Journal of Clinical Endocrinology & Metabolism , Volume 96 (Number 4). E669-E673. doi:10.1210/jc.2010-1782 ISSN 0021-972x.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1210/jc.2010-1782
Abstract
Context: The novel adipokine, nesfatin-1/NUCB-2, reduces food intake, levels of which are elevated in overweight individuals.
Objectives: The aim of the study was to investigate the mechanisms underlying brain nesfatin-1/ NUCB-2 uptake and to determine whether reduced uptake may contribute to nesfatin-1/NUCB-2 resistance.
Design: Cerebrospinal fluid (CSF) and corresponding plasma nesfatin-1/NUCB-2 were measured by ELISA [18 men and 20 women; age, 19-80 yr; body mass index (BMI), 16.2-38.1 kg/m(2)] and correlated to body adiposity and metabolic parameters.
Results: CSF/plasma nesfatin-1/NUCB-2 ratio was significantly negatively associated with BMI, body weight, fat mass, and CSF glucose. BMI was predictive of CSF/plasma nesfatin-1/NUCB-2 ratio (beta = -0.786; P = 0.045). CSF nesfatin-1/NUCB-2 was significantly positively associated with plasma nesfatin-1/NUCB-2 (R = 0.706; P < 0.01). There was a significant linear relation between CSF and plasma nesfatin-1/NUCB-2 in lean (BMI <25 kg/m(2); R = 0.744; P = 0.002) and obese (BMI >= 30 kg/m(2); R = 0.693; P = 0.026) subjects. Subjects in the highest plasma nesfatin-1/NUCB-2 quintile had lower CSF/plasma nesfatin-1/NUCB-2 ratio [26.5% (26.0-29.5%)] compared to the lowest plasma nesfatin-1/NUCB-2 quintile [38.5% (34.0-42.0%)] (P < 0.01), corresponding BMI [32.4 (31.0-35.0) vs. 23.3 (19.7-23.5) kg/m(2); P < 0.01], and fat mass [32.8 (29.5-40.6) vs. 30.7 (8.2-20.1) kg/m(2); P < 0.01].
Conclusions: Our observations have important implications with respect to the potential weight-reducing actions of nesfatin-1/NUCB-2 treatment. Future research should seek to clarify whether nesfatin-1/NUCB-2 would be beneficial in the management of obesity. (J Clin Endocrinol Metab 96: E669-E673, 2011)
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Subjects: | Q Science > QP Physiology R Medicine > RC Internal medicine |
||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016) Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
Library of Congress Subject Headings (LCSH): | Obesity -- Treatment, Proteins, Cerebrospinal fluid, Adipose tissues, Fat cells, Cytokines | ||||
Journal or Publication Title: | Journal of Clinical Endocrinology & Metabolism | ||||
Publisher: | Endocrine Society | ||||
ISSN: | 0021-972x | ||||
Official Date: | April 2011 | ||||
Dates: |
|
||||
Volume: | Volume 96 | ||||
Number: | Number 4 | ||||
Page Range: | E669-E673 | ||||
DOI: | 10.1210/jc.2010-1782 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Restricted or Subscription Access | ||||
Funder: | General Charities of the City of Coventry (GCCC) |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |